Drug Profile
K 11017
Latest Information Update: 24 May 2001
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Class Antineoplastics
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 24 May 2001 Discontinued-Preclinical for Glioma in USA (Unknown route)
- 14 Nov 1997 No-Development-Reported for Glioma in USA (Unknown route)
- 17 Oct 1996 Preclinical development for Glioma in USA (Unknown route)